Window Studies in Squamous Cell Carcinoma of the Head and Neck: Values and Limits

被引:13
作者
Zandberg, Dan P. [1 ]
Ferris, Robert L. [1 ]
机构
[1] UPMC Hillman Canc Ctr, 5150 Ctr Ave,5th Floor,Room 552, Pittsburgh, PA 15232 USA
关键词
Window trial; HNSCC; Neoadjuvant; Anti-PD-1; Immunotherapy; Targeted therapy; Cetuximab; GROWTH-FACTOR RECEPTOR; HUMAN-PAPILLOMAVIRUS; TARGETED THERAPY; PLUS CETUXIMAB; CANCER; CHEMOTHERAPY; OPPORTUNITY; RESISTANCE; ERLOTINIB; RECURRENT;
D O I
10.1007/s11864-018-0587-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Opinion statementIn head and neck cancer, we continue to work towards a more personalized approach to treatment of patients, where analysis of a patient's tumor guides targeting of molecular or immunologic pathways. Critically important to this pursuit is a better understanding of the direct biologic effect of a drug or combination on the tumor microenvironment in humans, as well as biomarker discovery. These goals are consistent with the primary purpose of a window of opportunity trial and while conduct of these trials requires a careful balance of benefits and potential risks, to date these trials have been both feasible and safe in HNSCC in the curative intent setting. In the era of immunotherapy, with countless possible combinations and ongoing clinical trials, window trials are even more important for informing clinical trial design and appropriate combination therapy, and ultimately a more personalized approach to our patients that leads to improvement in outcomes.
引用
收藏
页数:10
相关论文
共 35 条
  • [1] Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
    Ang, K. Kian
    Harris, Jonathan
    Wheeler, Richard
    Weber, Randal
    Rosenthal, David I.
    Nguyen-Tan, Phuc Felix
    Westra, William H.
    Chung, Christine H.
    Jordan, Richard C.
    Lu, Charles
    Kim, Harold
    Axelrod, Rita
    Silverman, C. Craig
    Redmond, Kevin P.
    Gillison, Maura L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (01) : 24 - 35
  • [2] Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer
    Bauman, Julie E.
    Duvvuri, Umamaheswar
    Gooding, William E.
    Rath, Tanya J.
    Gross, Neil D.
    Song, John
    Jimeno, Antonio
    Yarbrough, Wendell G.
    Johnson, Faye M.
    Wang, Lin
    Chiosea, Simion
    Sen, Malabika
    Kass, Jason
    Johnson, Jonas T.
    Ferris, Robert L.
    Kim, Seungwon
    Hirsch, Fred R.
    Ellison, Kimberly
    Flaherty, John T.
    Mills, Gordon B.
    Grandis, Jennifer R.
    [J]. JCI INSIGHT, 2017, 2 (06)
  • [3] Neoadjuvant anti-OX40 (MEDI6469) prior to surgery in head and neck squamous cell carcinoma.
    Bell, Richard Bryan
    Duhen, Rebekka
    Leidner, Rom S.
    Curti, Brendan D.
    Ballesteros-Merino, Carmen
    Piening, Brian
    Bernard, Brady
    Pucilowska, Joanna
    Bifulco, Carlo Bruno
    Fox, Bernard A.
    Duhen, Thomas
    Redmond, William L.
    Koguchi, Yoshinobu
    Cheng, Allen
    Patel, Ashish A.
    Morris, George
    Tamakawa, Raina
    Schuster, Mark W.
    Urba, Walter John
    Weinberg, Andrew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen
    Berinstein, Neil L.
    McNamara, Michael
    Nguyen, Ariane
    Egan, James
    Wolf, Gregory T.
    [J]. ONCOIMMUNOLOGY, 2018, 7 (05):
  • [5] Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
    Bonner, JA
    Harari, PM
    Giralt, J
    Azarnia, N
    Shin, DM
    Cohen, RB
    Jones, CU
    Sur, R
    Raben, D
    Jassem, J
    Ove, R
    Kies, MS
    Baselga, J
    Youssoufian, H
    Amellal, N
    Rowinsky, EK
    Ang, KK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) : 567 - 578
  • [6] Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
    Brand, Toni M.
    Iida, Mari
    Wheeler, Deric L.
    [J]. CANCER BIOLOGY & THERAPY, 2011, 11 (09) : 777 - 792
  • [7] A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F] F-AraG.
    Colevas, A. Dimitrios
    Bedi, Nikita
    Chang, Serena
    Nieves, Uriel Yojanan Moreno
    Chatterjee, Susmita
    Davidzon, Guido Alejandro
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Targeting epidermal growth factor receptor and Src pathways in head and neck cancer
    Egloff, Ann Marie
    Grandis, Jennifer R.
    [J]. SEMINARS IN ONCOLOGY, 2008, 35 (03) : 286 - 297
  • [9] Phase I clinical trial design in cancer drug development
    Eisenhauer, EA
    O'Dwyer, PJ
    Christian, M
    Humphrey, JS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 684 - 692
  • [10] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
    Ferris, R. L.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Iglesias Docampo, L. C.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Monga, M.
    Lynch, M.
    Geese, W. J.
    Kopit, J.
    Shaw, J. W.
    Gillison, M. L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1856 - 1867